By bringing together a world-class team of lung cancer scientists and clinicians from academic and community medical centers in the United States, United Kingdom, France, Italy and Spain, ALCMI has rapidly established a critical mass of scientific and operation expertise and infrastructure linked together to the benefit of patients through focused, translational research. ALCMI additionally has a number of active and in development research collaborations with diagnostic and therapeutic development companies designed to bring advances to patients today and tomorrow.
A. CASTLE – comprehensive genomic profiling and predictive treatment panels; established platform for discovery of diagnostics and targeted therapies
B. INHERIT EGFR T790M – inherited genes in high-risk families for screening and early detection
C. Genomics of Young Lung Cancer – causes and treatments for “young” lung cancer
